Shares of Mead Johnson Nutrition Co. (NYSE:MJN) have received a consensus recommendation of “Hold” from the thirteen ratings firms that are currently covering the firm. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $87.45.

MJN has been the topic of several research analyst reports. Susquehanna reissued a “hold” rating and issued a $90.00 price objective on shares of Mead Johnson Nutrition in a report on Wednesday, October 19th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $96.00 price target (down from $97.00) on shares of Mead Johnson Nutrition in a research note on Saturday, October 8th. Credit Suisse Group AG set a $95.00 price target on Mead Johnson Nutrition and gave the stock a “buy” rating in a research note on Wednesday, October 12th. Goldman Sachs Group Inc. lowered their price target on Mead Johnson Nutrition from $96.00 to $85.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 27th. Finally, Zacks Investment Research lowered Mead Johnson Nutrition from a “hold” rating to a “sell” rating in a research note on Tuesday, October 4th.

Mead Johnson Nutrition (NYSE:MJN) opened at 71.00 on Monday. The company has a 50-day moving average price of $76.89 and a 200-day moving average price of $83.06. The stock has a market capitalization of $13.12 billion, a PE ratio of 26.38 and a beta of 1.43. Mead Johnson Nutrition has a 12-month low of $65.53 and a 12-month high of $94.40.

Mead Johnson Nutrition (NYSE:MJN) last posted its earnings results on Thursday, October 27th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.86 by $0.01. The firm had revenue of $937.50 million for the quarter, compared to analyst estimates of $933.43 million. Mead Johnson Nutrition had a negative return on equity of 119.05% and a net margin of 13.26%. Mead Johnson Nutrition’s revenue for the quarter was down 4.1% compared to the same quarter last year. During the same period last year, the company earned $0.77 earnings per share. Analysts expect that Mead Johnson Nutrition will post $3.45 earnings per share for the current fiscal year.

In other news, Director Anna C. Catalano sold 656 shares of the stock in a transaction that occurred on Monday, October 31st. The stock was sold at an average price of $74.99, for a total transaction of $49,193.44. Following the completion of the transaction, the director now directly owns 8,796 shares of the company’s stock, valued at approximately $659,612.04. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.50% of the stock is owned by insiders.

Institutional investors have recently modified their holdings of the company. FMR LLC increased its position in shares of Mead Johnson Nutrition by 11.8% in the second quarter. FMR LLC now owns 13,045,067 shares of the company’s stock worth $1,183,840,000 after buying an additional 1,378,877 shares during the period. Vanguard Group Inc. boosted its stake in Mead Johnson Nutrition by 1.4% in the second quarter. Vanguard Group Inc. now owns 11,547,883 shares of the company’s stock worth $1,047,971,000 after buying an additional 154,730 shares in the last quarter. American Century Companies Inc. boosted its stake in Mead Johnson Nutrition by 15.2% in the second quarter. American Century Companies Inc. now owns 5,544,545 shares of the company’s stock worth $503,167,000 after buying an additional 732,011 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in Mead Johnson Nutrition by 2.1% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 5,132,654 shares of the company’s stock worth $405,531,000 after buying an additional 104,873 shares in the last quarter. Finally, Waddell & Reed Financial Inc. boosted its stake in Mead Johnson Nutrition by 47.0% in the second quarter. Waddell & Reed Financial Inc. now owns 4,274,094 shares of the company’s stock worth $387,874,000 after buying an additional 1,367,163 shares in the last quarter. 98.73% of the stock is owned by institutional investors and hedge funds.

Mead Johnson Nutrition Company Profile

Mead Johnson Nutrition Company (Mead Johnson) is a pediatric nutrition company. The Company manufactures, distributes and sells infant formulas, children’s nutrition and other nutritional products. The Company operates through three segments: Asia, North America/Europe and Latin America. Its product portfolio includes routine and specialty infant formulas, children’s milks and milk modifiers, dietary supplements for pregnant and breastfeeding mothers, pediatric vitamins, and products for pediatric metabolic disorders.

5 Day Chart for NYSE:MJN

Receive News & Stock Ratings for Mead Johnson Nutrition Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mead Johnson Nutrition Co. and related stocks with our FREE daily email newsletter.